Simple Summary Lutetium-177 prostate-specific membrane antigen radioligand therapy is an effective option for metastatic castration-resistant prostate cancer, yet a substantial proportion of patients progress early and no validated PSMA-PET/CT biomarker is available to identify them before treatment. In 63 patients, we...
M. Cuzzocrea, Giovanna Pecoraro, C. Iacovitti et al.· Cancers· 0 citations
The etiopathogenesis of prostate cancer (PCa) is complex and involves multiple hormonal and environmental factors. Among these, the role of infectious agents remains controversial. Human papillomavirus (HPV) is known to promote carcinogenesis in epithelial tumors and has also been detected, albeit inconsistently, in PC...
D. Brenna, Marialuisa Puglisi, Samantha Epistolio et al.· International Journal of Mol...· 0 citations
Delta-like ligand 3-directed therapies may reshape the management of DLL3-expressing prostate cancer if ongoing efforts to refine biomarkers improve patient enrichment and optimize trial design are successfully translated into clinical practice.
Giovanna Pecoraro, A. De Giorgi, G. Montelatici et al.· Drugs· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.